You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?

Article metrics

Article menu

Download PDFPDF

Commentary
Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?

 

Online download statistics by month:

Online download statistics by month: December 2019 to June 2025

AbstractFullPdf
Dec 201912120
Jan 202072722
Feb 202073739
Mar 2020777720
Apr 2020535339
May 2020777740
Jun 2020595914
Jul 2020909016
Aug 2020373736
Sep 2020525222
Oct 2020454514
Nov 2020505013
Dec 2020494913
Jan 2021565513
Feb 2021444412
Mar 2021555520
Apr 2021585836
May 2021494937
Jun 2021363629
Jul 2021454528
Aug 2021495031
Sep 2021666644
Oct 2021626253
Nov 2021717152
Dec 2021737342
Jan 2022515320
Feb 2022454522
Mar 2022424420
Apr 2022343515
May 2022676922
Jun 2022575722
Jul 2022525516
Aug 2022404015
Sep 2022434524
Oct 2022414121
Nov 2022313427
Dec 2022303016
Jan 2023606021
Feb 2023676826
Mar 2023838429
Apr 2023616129
May 2023696916
Jun 2023757527
Jul 2023737425
Aug 2023858524
Sep 2023575814
Oct 202310811038
Nov 202311411624
Dec 2023727223
Jan 2024293115
Feb 2024757513
Mar 202413213274
Apr 202411211238
May 2024929425
Jun 202411311325
Jul 202413513638
Aug 202412312024
Sep 202414214629
Oct 202416816831
Nov 202417517731
Dec 202420220544
Jan 202516316333
Feb 202521021157
Mar 202511911932
Apr 202510410427
May 202512212239
Jun 20259910128
Total518252191774